Idalopirdine – a small molecule antagonist of 5-HT6 with therapeutic potential against obesity

Abstract

5HT6 receptor antagonists offer the potential for safe and effective drugs against obesity, because they can reduce weight without causing serious side effects in the cardiovascular system. Also, their anorexic effect is associated with reduced food intake via an enhancement of satiety. In the present study we investigated the anorexic effect of idalopirdine (LuAE58054) in a model of obesity induced by high-fat diet. To induce obesity in rats, the animals were treated with feed with a fat content of 40 %. Body weight was controlled and the amount of food and water consumed was determined. The influence of the test compound on the lipid profile and glucose level was measured, as well as locomotor activity in home cages on the 20th day of the treatment. LuAE58054, at 5 mg kg−1/day i.p., was significantly anorectic in this model of obesity. Animals treated with LuAE58054 weighed 8 and 9.2 % less than the control obese animals on the 12th and 21st days, respectively. It significantly reduced food intake and the amount of peritoneal fat in animals, and reduced the level of triglycerides in plasma. LuAE58054 did not have a statistically significant effect on the spontaneous activity of diet-induced obese rats. The present study clearly demonstrates the effectiveness of LuAE58054 in reducing body weight. This compound is in phase III of clinical trials for the treatment of cognitive deficits associated with Alzheimer’s disease and schizophrenia. It is a 5HT6 receptor antagonist and is, therefore, free of those unacceptable side effects that preclude chronic use of anti-obesity drugs with other mechanisms of action. The search for an effective and safe anti-obesity drug is essential for an increasingly obese population; therefore, the anorectic action of LuAE58054 is important and there is a need for more research in this direction.

H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice

“…The spontaneous activity of the mice was measured on the fourteenth day of the treatment with a special, innovative RFID-system (Radio-frequency identification system) – TraffiCage (TSE-Systems, Germany). The test was conducted according to the method described in the literature (Dudek et al 2015a ; Dudek et al 2015b ; Dudek et al 2016 ). The animals had the transmitter (RFID) subcutaneously implanted, which tracked the time they spent in different areas of the cage.…”

Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro

“…The standard diet contained 100 g of feed-280 kcal. The spontaneous activity of rats was measured on the 1st, 14th and 20th day of the treatment with a special RFID-system-TraffiCage (TSE-Systems, Germany) [45,46]. The animals were subcutaneously implanted with transmitter identification (RFID), which enabled the presence and time spent in different areas of the cage to be counted; the data were then grouped in a special computer program.…”

Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET

“…Thus, with a multitude of interactions not fully elucidated, preclinical studies on both 5-HT 6 agonists and 5-HT 6 antagonists have shown efficacy against depression, anxiety, and cognitive impairment (1). In addition, 5-HT 6 antagonists have shown promise in the treatment of obesity (7), major depressive disorder (8), age-related cognitive decline (9), and schizophrenia (10). Currently available antidepressants and antipsychotics have also been shown to have a strong affinity for the 5-HT 6 receptor (11,12), adding speculation that these clinical effects might, at least in part, be mediated through this receptor.…”